Texas Medical Board Rules: In-Office Biologic Compliance

Texas Medical Board compliance rules for in-office biologic preparation require licensed physicians to maintain direct oversight of all autologous and allogeneic processing, ensure proper delegation protocols under TMB Chapter 193, and adhere to aseptic handling standards consistent with FDA 21 CFR 1271 regulations. Practices preparing biologics such as autologous blood components or handling tissue products must maintain detailed lot tracking, staff competency records, and environmental contamination controls to ensure patient safety and regulatory compliance. Proper alignment between clinical execution, operational procurement, and documentation protocols is essential for risk mitigation.

Regulatory Framework: FDA 21 CFR 1271 vs. TMB Standards

In-office biologic preparation sits at the intersection of federal FDA mandates and state-level medical board oversight. The Food and Drug Administration (FDA) regulates Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) under 21 CFR Part 1271. This regulatory structure divides biologics primarily into Section 361 products—which are minimally manipulated, intended for homologous use, and do not require pre-market approval—and Section 351 products, which involve systemic effects or extensive ex-vivo manipulation and are classified as drugs or biological products requiring formal approval.

While the FDA governs product classification, manufacturing standards, and labeling, the Texas Medical Board (TMB) regulates the practice of medicine within the state. For medical practice managers and medical directors, TMB compliance centers on physician responsibility, patient safety, informed consent, and the appropriate delegation of duties to non-physician staff. When a clinic processes point-of-care autologous tissue—such as platelet-rich plasma (PRP) or bone marrow concentrate—the TMB views the procedure as part of the practice of medicine. Consequently, the operating physician retains legal and professional accountability for the quality, safety, and appropriateness of the processing procedure.

Clinics must ensure that any specialized equipment, centrifuges, or closed-system blood draw equipment used in the office adhere to clear medical-grade standards. For practices evaluating their current product mix, selecting compliant biologics and tissue products sourced from licensed distributors is the first line of defense against regulatory scrutiny.

Physician Delegation and Supervision Standards Under TMB Chapter 193

Under Texas Administrative Code (TAC) Title 22, Part 9, Chapter 193, the Texas Medical Board outlines precise requirements for physician delegation of medical acts. In-office biologic preparation and administration frequently involve mid-level practitioners (Physician Assistants and Advanced Practice Registered Nurses) or medical assistants. Remaining compliant requires strict adherence to the following supervisory structures:

1. Written Standing Delegation Orders (SDOs): Any non-physician staff member preparing or administering a biologic must operate under detailed, written SDOs signed by the supervising physician. These orders must specify the exact procedures allowed, step-by-step preparation protocols, handling parameters, and emergency measures.
2. Verified Competency Logs: The supervising physician must document initial and ongoing training for all staff handling centrifuges, blood collection, or sterile allograft preparation. Annual re-assessment of competency is highly recommended.
3. Direct vs. General Supervision: While certain routine blood draws can occur under general supervision, the preparation and immediate reinjection of autologous tissue products require clear protocol boundaries. The physician must remain accessible and actively maintain oversight of diagnosis, treatment planning, and procedure clearance.
4. Patient-Specific Orders: Delegation orders do not replace individualized medical necessity. Every biologic intervention must follow a documented physician evaluation confirming that the treatment is appropriate for the patient's specific clinical presentation.

Operational Checklist: In-Office Processing and Storage Requirements

Maintaining a compliant clinical workspace requires systematic protocols covering infection control, temperature management, and chain-of-custody tracking. Practice managers should audit their clinic workflow against the following operational checklist:

• Environment and Equipment Hygiene:
• Dedicated preparation surface distinct from routine diagnostic or administrative areas.
• Daily cleaning protocols using EPA-registered disinfectant agents effective against bloodborne pathogens.
• Routine calibration and preventative maintenance schedules for all centrifuge devices and biological safety cabinets.
• Cold Chain and Environmental Control:
• Continuous temperature monitoring for refrigerators and freezers storing tissue products or compounding supplies.
• Calibrated digital logging devices with high/low temperature alarms.
• Documented disposal procedures for any biologic compromised by temperature excursions beyond manufacturer specifications.
• Chain of Custody and Documentation:
• Logbooks or Electronic Health Record (EHR) integration tracking lot numbers, expiration dates, patient identifiers, and timestamps for draw, centrifugation, and administration.
• Verification of single-use status for all consumables, needles, tubes, and processing kits obtained through verified medical supplies distributors.
• Waste Management:
• Immediate biohazard disposal for processing kits, blood collection sets, and discarded fluid layers in compliance with state biohazardous waste disposal standards.

Clinical vs. Operational Perspectives on Biologic Preparation

Achieving total compliance requires bridging the gap between clinical intent and administrative execution. Both roles view in-office preparation through distinct, complementary lenses.

Clinical Perspective: Chain of Custody and Patient Outcomes

For clinicians, compliance is ultimately about patient safety, sterility, and treatment efficacy. The treating physician must verify that the preparation protocol does not compromise cell viability or introduce exogenous contaminants. Clinical considerations include:

• Homologous Use Criteria: Ensuring that the biologic applied matches the original function of the tissue in the donor or harvest site, adhering to FDA guidelines.
• Minimal Manipulation Limits: Avoiding ex-vivo enzymatic digestion, cell expansion, or chemical additions that alter the biological characteristics of the tissue.
• Aseptic Handling: Exercising strict sterile technique from vein puncture or tissue draw through final administration to prevent post-procedure infection.

Operational Perspective: Procurement, Inventory, and Risk Mitigation

For practice managers and procurement administrators, compliance focuses on liability reduction, workflow efficiency, and supply chain integrity. Practice managers serving regenerative medicine doctors must focus on:

• Vendor Due Diligence: Verifying that supply vendors hold valid Texas state distributor licenses (such as Texas Department of State Health Services device/drug distributor licensing).
• Standardized Cost-Per-Treatment: Ensuring that validated, closed-system processing kits are stocked reliably without supply interruptions, keeping per-procedure cost predictable.
• Audit Readiness: Maintaining complete documentation trails so that any TMB audit or liability inquiry can be met with instant, comprehensive records of delegation orders, training logs, and lot numbers.

What This Means for Your Practice

Navigating TMB regulations for in-office biologic preparation requires proactive management rather than reactive adjustments. To ensure your practice remains fully compliant while delivering high-quality patient care, administrators should take the following concrete steps:

1. Conduct an SDO Audit: Review all existing Standing Delegation Orders related to biologic preparation, centrifugation, and administration. Ensure they are signed, dated within the past 12 months, and reflect current staff responsibilities.
2. Inspect Vendor Credentials: Confirm that all distributors supplying your point-of-care preparation kits, blood draw tubes, laser devices, or allograft tissues hold appropriate Texas licensing. Learn more about compliant sourcing on our about page.
3. Implement Digital Lot Tracking: Transition manual preparation logs into standardized digital templates linked to the patient's EHR to ensure mandatory tracking of lot numbers, equipment serial numbers, and expiration dates.
4. Standardize Staff Training: Schedule formal quarterly reviews of aseptic technique, handling protocols, and emergency response for all clinical personnel participating in biologic preparation.

Partner with Licensed Texas Experts

Dallas Regenerative Solutions supplies Texas clinics with fully compliant, medical-grade processing kits, specialized devices, and high-quality biologics backed by clear licensing and rigorous regulatory adherence. Our team works directly with practice managers and medical directors to optimize clinical workflows, lower cost per treatment, and ensure seamless procurement.

To schedule a compliance-focused product and procurement consultation for your practice, contact Dallas Regenerative Solutions today.